# Tandem Pharmacy Track at the 2024 Tandem Meetings | Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR February 23-24, 2024 San Antonio, Texas

\*\*\* IMPORTANT: The Pharmacy Track only offers pharmacy credits

If you are seeking pharmacy credits, you must complete the **pharmacy CE evaluation/attestation** using the link

below

(https://surveys.francefoundation.com/s3/Tandem-Pharmacy-2024)

The 2024 Tandem Meetings overall meeting evaluation does not capture pharmacy CE requests

# Target Audience

This activity is intended for clinical pharmacists, residents, and nurses who specialize in, or are training in, blood and marrow transplantation (BMT).

# Program Overview

The Tandem Pharmacy Track is a 2-day session held annually in conjunction with the Tandem Meetings of ASTCT and CIBMTR. This track features leaders of the pharmacy profession specializing in HCT and cellular therapy, along with their colleagues and experts from other medical disciplines, who provide perspective and an evidence-based approach to the emerging issues and clinical management of this complex patient population.

# **Overall Program Learning Objectives**

- Discuss current clinical practice and challenges for pharmacists in the field of hematopoietic stem cell transplantation (HCT) and cellular therapy
- Identify best practice strategies and clinical challenges related to post-transplant cyclophosphamide use, optimal choices for cytomegalovirus and viral-directed t-cell therapy, reduced intensity conditioning regimens, and management of CAR-T cytopenia toxicities
- Analyze strategies in statistics to facilitate HCT-related pharmacy research, and implementation of a clinic pharmacy practice
- Identify challenges in the HCT patient population with regard to off-label medication use and administration
- Discuss optimal use of CAR-T therapies and Bi-specific antibodies in lymphoma patients
- Examine considerations for gene therapy in hemoglobinopathies, atypical chronic graft versus host disease, and post-transplant acute myeloid leukemia maintenance

# **INSTRUCTIONS FOR PARTICIPATION AND REQUESTING PHARMACY CREDIT**

- 1. There are no fees for participating in and receiving credit for this activity
- 2. Review the activity objectives and Pharmacy CE information
- 3. Complete the Pharmacy CE activity
- 4. Complete the **Pharmacy CE evaluation/attestation** form by visiting the link below <u>https://surveys.francefoundation.com/s3/Tandem-Pharmacy-2024</u>

This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.

# Please note that this evaluation is separate from the overall Tandem conference evaluation and must be completed to receive Pharmacy credit.

Technical Requirements: http://www.francefoundation.com/general-requirements.html

# **Credit Fulfillment**

• If you are a pharmacist requesting ACPE credits, your credit request will be uploaded to CPE Monitor within 60 days

# ACCREDITED PROVIDER

This activity is jointly provided by The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT).







In support of improving patient care, this activity has been planned and implemented by The France Foundation and the American Society for Transplantation and Cellular Therapy (ASTCT). The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the

JOINTLY ACCREDITED PROVIDER

ducation (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

#### PHARMACISTS



This knowledge and application-based activity qualifies for 12.5 contact hours (0.125 CEUs) of continuing pharmacy education credit. Please submit all evaluations and credit requests no later than 30 days after you complete this activity to ensure your credit fulfillment, as CE credit cannot be awarded past 60 days from the activity date. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).

To request pharmacy credit, you MUST complete THIS survey: https://surveys.francefoundation.com/s3/Tandem-Pharmacy-2024

All other healthcare professionals completing this course will be issued a statement of participation.

# Activity Agenda & Faculty 2024 Tandem Pharmacy Track Schedule

Time	Presentation	Speaker	UAN Number	CE	
	Day 1 (total = 6.5 CE)				
8:00-8:15	Welcome/Overview 2024 Pharmacy Conference	Kelsey Konrardy, PharmD, BCOP			
8:15-8:45	Becoming a Clinical Pharmacist: Starting a New Practice	Joseph Bubalo, PharmD, BCPS, BCOP	JA0007204- 9999-24-002- L01-P	0.5	
8:45-9:15	Pharmacy SIG Update	Terri Lynn Shigle, PharmD, BCOP	JA0007204- 9999-24-003- L01-P	0.5	
9:15-10:00	ASH Updates Part 1	Sandy On, PharmD, BCOP Jamie Elsner Ziggas, PharmD, BCOP	JA0007204- 9999-24-004- L01-P	0.75	
10:00- 10:15	Morning Break				
10:15- 11:00	ASH Updates Part 2	Rebecca Worden, PharmD, BCOP Rebecca Gonzalez, PharmD, BCOP	JA0007204- 9999-24-005- L01-P	0.75	
11:00- 12:00	Management of Cytopenia Post CAR T-cell Therapy: A US and UK Perspective <b>(BCOP)</b>	Mary McGann, PharmD, BCOP Brijesh Gautama, MPharm (Hons), PGDip	JA0007204- 9999-24-006- L01-P	1.0	
12:00-1:00	Lunch Break				
1:00-2:00	GENEie in a Bottle: Gene Therapy for Hemoglobinopathies <b>(BCOP)</b>	Alexis Kuhn, PharmD, BCOP	JA0007204- 9999-24-007- L01-P	1.0	
2:00-2:30	Atypical Chronic Graft-Versus- Host Disease: Challenges in Chronic GVHD Diagnosis	Geoff Cuvelier, MD, FRCPC	JA0007204- 9999-24-008- L01-P	0.5	

2:30-3:00	STAT PRIME: Statistical Considerations and Common Pitfalls of Time-to-Event Analysis in Hematopoietic Stem Cell Transplantation and Cellular Therapy Studies	Piyanuch Kongtim, MD, PhD	JA0007204- 9999-24-009- L01-P	0.5		
3:00-3:15	Afternoon Break					
3:15-4:15	Best Abstracts Presentations	Jitesh Kawedia, PharmD, PhD	JA0007204-9999- 24-010-L01-P	1.0		
		Susie Long, PharmD				
		Andrew Lin, PharmD, BCOP				
	Day 2 (total = 6.0 CE)					
Time	Presentation	Speaker	UAN Number	CE		
8:00-8:15	Welcome/Overview 2024 Pharmacy Conference	Nicole Daukshus, PharmD, BCOP				
8:15-9:30	Cracking the Cy Code: A Best Practice Panel on Post- transplant Cyclophosphamide	Justin Graff, PharmD, BCOP Timothy Porter, PharmD, BCOP	JA0007204-9999- 24-011-L01-P	1.25		
		Erika Wass, PharmD, BCOP				
9:30-10:00	Recent Updates in Cytomegalovirus Prevention and Treatment	Justin Tossey, PharmD, BCOP	JA0007204-9999- 24-012-L01-P	0.5		
		Terri Lynn Shigle, PharmD, BCOP				
10:00- 10:30	Morning Break					
10:30- 11:00	Viral Specific T-cell Immunotherapy	Amanda Olsen, MD	JA0007204-9999- 24-013-L01-P	0.5		
11:00- 12:00	Taking a Bite Out of CAR-T: Debating Use of CAR T-cell Therapy Versus Bispecific Antibodies in Lymphoma <b>(BCOP)</b>	Emilie Aschenbrenner, PharmD, BCOP Katie Gatwood, PharmD, BCOP	JA0007204-9999- 24-014-L01-P	1.0		

12:00-1:00	Lunch Break			
1:00-1:45	Are You Sure We Can Do That? Alternative Administration and Off-label Use of Medication in Hematopoietic Stem Cell Transplant Patients	Nicole Daukshus, PharmD, BCOP Breana Goscicki, PharmD, BCPPS	JA0007204-9999- 24-015-L01-P	0.75
1:45-2:00	Afternoon Break			
2:00-3:00	Post-transplant Maintenance Therapy for Acute Myeloid Leukemia <b>(BCOP)</b>	Andrew Lin, PharmD, BCOP	JA0007204-9999- 24-016-L01-P	1.0
	Afternoon Break			
3:15-4:15	Conditioning Regimens: The Great Debate	Shawn Griffin, PharmD, BCOP	JA0007204-9999- 24-017-L01-P	1.0
		Victoria Jensen, PharmD, BCOP		

# **Disclosure Policy**

The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.

Disclosures for members of the planning committee and faculty will be disclosed to learners prior to the conference and can also be found <u>here</u>.

#### **Disclosure of Unlabeled Use**

The France Foundation (TFF) and The American Society for Transplantation and Cellular Therapy (ASTCT) require CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion.

Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

### **Commercial Support Acknowledgment**

No commercial support was provided for this activity.

#### **Disclaimer**

The France Foundation and the American Society for Transplantation and Cellular Therapy present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, the American Society for Transplantation and Cellular Therapy, and the commercial supporter(s) assume no liability for the information herein.

#### **CONTACT INFORMATION**

If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.